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Introduction
Accumulation of misfolded proteins hampers the function of 
the ER and elicits a variety of stress responses that might even-
tually result in cell death. The capacity to rapidly remove fold-
ing-defective  polypeptides  from  the  ER  lumen  is  therefore 
crucial to maintain cell homeostasis (Malhotra and Kaufman, 
2007; Ron and Walter, 2007; Yoshida, 2007). Polymerogenic, 
misfolded proteins such as ATZ, a folding-defective, aggrega-
tion-prone mutant of the secretory protein 1-antitrypsin, and 
serpins are removed from the ER upon activation of multiple 
proteasome-dependent  and  proteasome-independent  disposal 
pathways including autophagy (Perlmutter, 2006; Shen et al., 
2006; Granell and Baldini, 2008; Kroeger et al., 2009; Rutledge 
et al., 2009). Normally, however, misfolded proteins produced 
in the ER are extracted from folding machineries and are dis-
located across the ER membrane to be degraded by cytosolic 26S 
proteasomes in a series of tightly regulated events collectively 
defined  as  ER-associated  degradation  (ERAD;  McCracken   
and Brodsky, 1996). Most of the polypeptides entering the ER 
lumen are modified with preassembled glucose3-mannose9- 
N-acetylglucosamine2-oligosaccharides,  which  are  covalently 
attached to Asn side chains in Asn-Xxx-Ser/Thr sequons emerg-
ing in the ER lumen. Stepwise processing of protein-bound 
oligosaccharides eventually determines the fate of the covalently 
linked polypeptide chains (for review see Molinari, 2007). For 
instance, degradation of terminally misfolded glycoproteins from 
the ER requires extensive demannosylation of the protein-bound 
oligosaccharides, which precedes polypeptide dislocation across 
the ER membrane and degradation (Hebert and Molinari, 2007; 
Nakatsukasa and Brodsky, 2008; Lederkremer, 2009). Current 
models claim that dislocation across the ER membrane follows 
specific pathways regulated by luminal, transmembrane, and cyto-
solic complexes built around membrane-embedded E3 ubiqui-
tin ligases (Kostova et al., 2007; Nakatsukasa  and  Brodsky, 
2008; Ravid and Hochstrasser, 2008; Hirsch et al., 2009). In 
Saccharomyces cerevisiae, disposal of transmembrane proteins 
with cytosolic defects (ERAD-C substrates) requires interven-
tion of the DOA10 pathway. Membrane-anchored polypeptides 
with transmembrane lesions (ERAD-M substrates) as well as 
membrane-tethered and soluble polypeptides with lesions in 
the ER lumen (ERAD-L substrates) are cleared from the ER 
  S
ophisticated  quality  control  mechanisms  pro-
long retention of protein-folding intermediates in   
the endoplasmic reticulum (ER) until maturation 
while  sorting  out  terminally  misfolded  polypeptides 
for  ER-associated  degradation  (ERAD).  The  presence 
of structural lesions in the luminal, transmembrane, or 
cytosolic domains determines the classification of mis-
folded polypeptides as ERAD-L, -M, or -C substrates 
and results in selection of distinct degradation path-
ways. In this study, we show that disposal of soluble 
(nontransmembrane) polypeptides with luminal lesions 
(ERAD-LS  substrates)  is  strictly  dependent  on  the  E3 
ubiquitin ligase HRD1, the associated cargo receptor 
SEL1L,  and  two  interchangeable  ERAD  lectins,  OS-9 
and XTP3-B. These ERAD factors become dispensable 
for degradation of the same polypeptides when mem-
brane tethered (ERAD-LM substrates). Our data reveal 
that, in contrast to budding yeast, tethering of mamma-
lian ERAD-L substrates to the membrane changes selec-
tion of the degradation pathway.
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Few of these components do not participate in the GP78 or in 
other dislocation complexes (Hosokawa et al., 2008; Morito 
et al., 2008; Alcock and Swanton, 2009). Therefore, certainly 
the different composition of the complexes built around mem-
brane-embedded  E3  ubiquitin  ligases  determines  substrate 
selection, but which substrate feature is relevant to determine 
whether a misfolded polypeptide will preferentially use one or 
the other ERAD pathway is unknown.
To better understand this, we compared the requirements for 
efficient disposal of two canonical, N-glycosylated, membrane- 
anchored ERAD substrates, BACE476 (Molinari et al., 2002) 
and  CD3-  (Yang  et  al.,  1998),  with  the  requirements  for   
efficient disposal of their variants lacking the transmembrane 
anchor (BACE476 and CD3-; Fig. 1). For all of these pro-
teins, extensive demannosylation is required for ERAD. Our 
data reveal that only degradation of the soluble (nontransmem-
brane)  variants  of  BACE476  and  CD3-  strictly  depend  on 
several participants of the HRD1 pathway regulating ERAD, 
namely the E3 ubiquitin ligase HRD1, the HRD1-associated 
cargo receptor SEL1L, and the ERAD lectins OS-9 and XTP3-B. 
Disposal of the membrane-tethered variants of the same folding- 
defective polypeptides remained unperturbed upon inactivation 
of HRD1, SEL1L, and, significantly, OS-9 and XTP3-B. Thus, in 
contrast to yeast (Quan et al., 2008; Clerc et al., 2009), substrate 
demannosylation in the mammalian ER is not (only) required to 
generate a signal for disposal decoded by the ERAD lectins of 
the OS-9 family. In fact, at least when the folding-defective 
glycopolypeptide is tethered at the ER membrane, interven-
tion of OS-9 and XTP3-B becomes dispensable for efficient 
disposal. Moreover, and again in contrast to yeast (Taxis et al., 
2003; Willer et al., 2008), the presence or the absence of a mem-
brane anchor alters selection of the disposal pathway used by 
ERAD-L substrates in mammalian cells. This was confirmed 
by the finding that the crucial dependency on components of 
the HRD1 pathway for degradation of NHK, another classical 
ERAD-L substrate (Liu et al., 1997), was substantially relieved 
when the protein was anchored at the ER membrane. Our data 
lead us to group polypeptides with structural lesions in the ER 
lumen in two subclasses, namely ERAD-LS substrates (for solu-
ble ERAD-L substrates whose disposal is strictly dependent on 
the HRD1 pathway) and ERAD-LM substrates (for membrane- 
tethered ERAD-L substrates for which alternative ERAD path-
ways can be activated to ensure efficient disposal). Our data 
through the HRD1 pathway (Taxis et al., 2003; Huyer et al., 
2004; Vashist and Ng, 2004; Carvalho et al., 2006; Denic et al., 
2006; Gauss et al., 2006; Willer et al., 2008).
The mammalian system is more complex. The mamma-
lian ER membrane contains several E3 ubiquitin ligases. Few 
of them (e.g., RNF5/RMA1, TEB4, TRC8, and RFP2) are still 
poorly characterized and/or have a restricted number of sub-
strates (Younger et al., 2006; Lerner et al., 2007; Morito et al., 
2008; Wang et al., 2008; Hirsch et al., 2009; Stagg et al., 
2009). Others, such as synoviolin/HRD1 and GP78, are better 
characterized and regulate, in a concerted action with several 
interacting partners, disposal of numerous folding-defective 
polypeptides used as model ERAD substrates (Kostova et al., 
2007; Nakatsukasa and Brodsky, 2008; Ravid and Hochstras-
ser, 2008; Hirsch et al., 2009).
Individual substrates follow preferential routes for dis-
location across the mammalian ER membrane. Consistently, 
inactivation  of  the  GP78  pathway  is  sufficient  to  substan-
tially delay disposal of conventional ERAD substrates such 
as TCR, CD3-, and CFTRF508 (Fang et al., 2001; Zhong 
et al., 2004; Ballar et al., 2006; Chen et al., 2006; Vij et al., 
2006; Tsai et al., 2007; Morito et al., 2008), but it does not 
affect disposal of other classical ERAD substrates such as 
null  Hong  Kong  (NHK)  or  Ri332.  However,  inactivation  of 
HRD1  or  of  components  of  the  multimeric  complex  built 
around this E3 ligase has no consequence on disposal of GP78 
clients (Nadav et al., 2003; Song et al., 2005; Cao et al., 2007; 
Yang et al., 2007; Morito et al., 2008; Riemer et al., 2009) 
but specifically interferes with disposal of folding-defective 
polypeptides such as NHK, Ri332, Igµs, IgLC, IgHC, and   
IgLC  (Liang  et  al.,  2003;  Mueller  et  al.,  2006;  Okuda-
  Shimizu and Hendershot, 2007; Yang et al., 2007; Bernasconi 
et al., 2008; Brodsky and Fisher, 2008; Cattaneo et al., 2008; 
Christianson et al., 2008; Hosokawa et al., 2008; Alcock and 
Swanton, 2009; and references therein). Because the reasons 
behind this substrate specificity are unknown, it is impossible 
to predict which pathway will be used by a given folding- 
defective polypeptide.
ERAD  substrates  recruitment  to  HRD1  occurs  either   
directly or indirectly through transient associations of the HRD1 
cofactor SEL1L with luminal acceptors such as OS-9, XTP3-B,   
EDEM1, BiP, or GRP94 (Mueller et al., 2006, 2008; Christianson   
et al., 2008; Hosokawa et al., 2008; Cormier et al., 2009). 
Figure 1.  Schematic representation of the seven 
canonical  ERAD  substrates  used  in  this  study. 
BACE476, CD3-, NHKBACE, and NHKCD3 are 
type I membrane proteins (ERAD-LM substrates); 
BACE476∆, CD3-∆, and NHK are the corre-
sponding soluble ERAD-LS substrates.225 Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al.
The labeled ERAD candidates had faster mobility at the 
end (Fig. 2, A and B, lanes 3 and 6) than at the beginning of the 
chase (Fig. 2, A and B, lanes 1 and 4). This is caused by the pro-
gressive demannosylation of ER-retained, misfolded polypep-
tides that reduces their apparent molecular weight. Extensive 
demannosylation interrupts futile folding attempts in the cal-
nexin chaperone system and promotes substrate deviation in the 
ERAD pathway (for review see Molinari, 2007). Consistently, 
the progressive increase in BACE electrophoretic mobility and 
BACE disposal were inhibited by kifunensine, a specific inhibi-
tor of 1,2-mannosidases (Fig. S1, A and B, lane 3). Deletion of 
HRD1 substantially delayed BACE476 disposal without affect-
ing the enhancement of BACE mobility, thus the extensive de-
mannosylation that precedes BACE ERAD. This shows that, in 
the series of luminal events leading to BACE destruction, i.e., 
(a) folding attempts phase in the calnexin cycle (Molinari et al., 
2002), (b) extraction from the folding machinery facilitated 
by substrate demannosylation (Molinari et al., 2002, 2003),   
(c) delivery at the ER membrane, (d) and dislocation across the 
ER membrane, the deletion of HRD1 only interferes with late 
events, as expected for a component of the dislocation machinery.
further highlight the more significant complexity and the some-
what different mechanisms regulating protein quality control in 
the mammalian versus the budding yeast ER.
Results
Consequences of HRD1 deletion on 
disposal of membrane-anchored and  
soluble BACE476
Availability  of  mouse  embryonic  fibroblasts  (MEFs)  lacking 
HRD1 (Yagishita et al., 2005) prompted us to assess the involve-
ment of this membrane-embedded E3 ubiquitin ligase in disposal 
of folding-defective polypeptides from the ER lumen. Hrd1
/ 
cells are more sensitive to ER stress-induced apoptosis, but they 
are not under ER stress (Fig. S2 C; Yagishita et al., 2005).
Tissue-specific  versions  of  the  human  -secretase 
(BACE501; Vanoni et al., 2008) are among the best-characterized   
ERAD substrates. For example, the type I membrane glyco-
protein BACE476 and its soluble variant BACE476 originate 
from alternative splicing of the BACE transcripts, resulting 
in a 25-residue deletion in the protein’s luminal ectodomain. 
This  deletion  prevents  attainment  of  the  native  structure   
when  the  polypeptide  is  ectopically  expressed  in  cultured 
mammalian cells (Molinari et al., 2002). BACE variants are 
defined as canonical ERAD substrates because their degrada-
tion requires extensive demannosylation of the protein-bound 
oligosaccharides (Fig. S1; Molinari et al., 2002), is acceler-
ated in cells expressing high levels of EDEM1 and EDEM2 
(Molinari et al., 2003; Olivari et al., 2005, 2006), is delayed 
in cells with low content of EDEM proteins (Molinari et al., 
2003), and is performed in the cytosol upon P97-facilitated 
extraction by 26S proteasomes (Fig. S1; Molinari et al., 2002; 
Wang et al., 2006).
BACE476 (Fig. 2 A) and BACE476 (Fig. 2 B) were indi-
vidually expressed in wild-type MEFs (wt; lanes 1–3) and MEFs 
lacking HRD1 (Hrd1
/; lanes 4–6). 17 h  after  transfection 
with appropriate expression plasmids, cells were pulsed for 
10  min with [
35S]methionine and cysteine and were subse-
quently  chased  in  normal  cell  culture  media  for  the  times 
shown in Fig. 2 (A and B). At the end of each chase time, cells 
were detergent solubilized, and the residual amount of radio-
labeled ERAD substrate was immunoisolated from postnuclear 
supernatants (PNSs) with specific antibodies (Fig. S2 A), sepa-
rated on SDS polyacrylamide gels, and quantified.
The kinetics of BACE476 disposal was essentially the 
same in cells with (Fig. 2 A, lanes 1–3) and without HRD1 
(Fig. 2 A, lanes 4–6). In both cell lines, only 30% of the ini-
tial amount of radiolabeled polypeptide was immunoisolated 
from PNS after a 6-h chase (Fig. 2 A, quantification). However, 
HRD1 deletion substantially delayed disposal of the same pro-
tein lacking a transmembrane anchor. In fact, only 20% of the 
initial amount of BACE476 was immunoisolated from lysates 
of wt cells after a 4-h chase (Fig. 2 B, lane 3 and quantification), 
whereas cells lacking HRD1 still contained 80% of the initial 
amount of labeled protein (Fig. 2 B, lane 6 and quantification). 
Therefore, HRD1 deletion selectively impaired disposal of the 
soluble variant of BACE476.
Figure 2.  Involvement of HRD1 in disposal of membrane-tethered and 
soluble BACE476. (A) Radiolabeled BACE476 was immunoisolated after 
the indicated chase times from wild-type MEFs (wt; lanes 1–3) or MEFs 
lacking HRD1 (Hrd1
/; lanes 4–6). Relevant bands were quantified and 
plotted. (B) Same as described in A for BACE476∆. (C) Radiolabeled 
BACE476∆ was immunoisolated after the indicated chase times from cells 
lacking HRD1 transfected with an empty plasmid (mock; lanes 1–3), a plas-
mid for expression of wild-type HRD1 (lanes 4–6), or a plasmid for expres-
sion of inactive HRD1 (HRD1*; lanes 7–9). Relevant bands were quantified 
and plotted. Error bars represent standard deviation (n = 2). Molecular 
mass markers are shown on the left for all gels (given in kilodaltons).JCB • VOLUME 188 • NUMBER 2 • 2010   226
and C [lanes 1–3]). We concluded that an active HRD1 path-
way is required for efficient degradation of BACE476 from 
the mammalian ER. Experiments performed to assess conse-
quences of ectopic expression of active or inactive HRD1 on 
disposal of BACE476 in cells lacking this E3 ubiquitin ligase 
confirmed dispensability of the HRD1 activity when the same 
folding-defective  ERAD  substrate  was  tethered  at  the  ER 
membrane (Fig. S3 A).
Consequences of HRD1 deletion on 
disposal of membrane-anchored and  
soluble CD3-
CD3- is a type I membrane glycoprotein, which is typically 
part of the T cell receptor–CD3 complex involved in T cell 
development and signal transduction. When expressed indi-
vidually, the CD3- orphan subunit cannot attain its native 
structure and is degraded from the ER with mechanisms that 
have been thoroughly characterized. In particular, CD3- deg-
radation requires demannosylation and is operated by cyto-
solic proteasomes (Yang et al., 1998). CD3- is a client of the 
E3 ubiquitin ligase GP78 (Fang et al., 2001; Zhong et al., 
2004; Ballar et al., 2006; Chen et al., 2006; Tsai et al., 2007), 
and it has been reported that RFP2, another E3 ligase, contrib-
utes to its disposal (Lerner et al., 2007). Down-regulation of 
HRD1 does not affect CD3- degradation (Yang et al., 2007), 
although  it  has  recently  been  reported  that  down-regulation   
of HRD1 might result in increased intracellular levels of 
GP78 (Shmueli et al., 2009; Ballar et al., 2010). Therefore, 
it was not unexpected that CD3- clearance from the ER 
lumen  occurred  with  similar  kinetics  in  wild-type  cells 
(Fig. 3 A, lanes 1–3) and in cells lacking HRD1 (Fig. 3 A, 
lanes 4–6).
The anchorless variant of CD3- was also efficiently re-
tained in the ER as confirmed by lack of secretion in the extra-
cellular  media  (Fig.  S2  E).  As  for  the  membrane-tethered 
version of the protein, CD3- degradation required demanno-
sylation and was operated by cytosolic proteasomes. Signifi-
cantly,  however,  deletion  of  the  CD3-  membrane  anchor 
converted this GP78/RFP2 client protein to an HRD1 client. In 
fact, degradation of the anchorless CD3- was defective in 
cells lacking HRD1 (Fig. 3 B, lanes 4–6 and quantifications). 
HRD1 deletion inhibited CD3- disposal without affecting the 
extensive substrate demannosylation that signals prolonged ER 
retention of this folding-defective polypeptide.
As in the case of BACE476, to avoid spurious pheno-
types possibly caused by uncharacterized differences between 
wild-type and knockout cell lines, we confirmed involvement 
of HRD1 by showing that CD3- disposal was defective in 
cells lacking HRD1 or expressing the inactive form of HRD1 
(t1/2 > 120 min; Fig. 3 C, lanes 1–3 and 7–9, respectively) but 
progressed with wild-type kinetics (t1/2 < 60 min; Fig. 3 C, lanes 
4–6) upon back transfection of active HRD1 in the knockout 
cells. The finding that an active HRD1 pathway is required for 
efficient degradation of CD3- but not for disposal of the 
same protein when associated with the ER membrane was con-
firmed by assessing the dispensability of HRD1 for CD3- dis-
posal (Fig. S3 B).
HRD1 activity is required for efficient 
disposal of BACE476
To avoid spurious phenotypes possibly caused by uncharacter-
ized differences between wild-type and knockout cell lines, 
we confirmed that HRD1 is required for efficient disposal of 
BACE476 by reproducing the experiments shown in Fig. 2   
(A and B) in a single cell line. To this end, we compared degra-
dation of BACE476 in Hrd1 knockout cells mock transfected 
(Fig. 2 C, lanes 1–3) and in the same cell line expressing an 
active (HRD1; Fig. 2 C, lanes 4–6; and Fig. S2 B) or inac-
tive form (the C307S mutant HRD1*; Fig. 2 C, lanes 7–9; and 
Fig. S2 B; Amano et al., 2003) of HRD1. In all experiments, 
BACE476 was efficiently retained in the ER and degraded 
as confirmed by the lack of BACE476 secretion (Fig. S2 D). 
BACE476 had t1/2 > 240 min in cells lacking HRD1 (for de-
termination of protein t1/2 see Materials and methods; Fig. 2,   
B [lanes 4–6] and C [lanes 1–3]). Back transfection of the 
active form of HRD1 accelerated disposal of BACE476 to 
a rate (t1/2 = 150 min; Fig. 2 C, lanes 4–6) approaching the 
disposal rate measured in wild-type cells (Fig. 2 B, lanes 1–3 
and quantifications). In cells expressing the inactive form of   
HRD1, disposal of BACE476 (t1/2 > 240 min; Fig. 2 C, lanes 7–9) 
was as slow as in cells lacking HRD1 (Fig. 2, B [lanes 4–6] 
Figure 3.  Involvement of HRD1 in disposal of membrane-tethered and 
soluble CD3-. (A) Radiolabeled CD3- was immunoisolated after the in-
dicated chase times from wild-type MEFs (wt; lanes 1–3) or from MEFs 
lacking  HRD1  (Hrd1
/;  lanes  4–6).  Relevant  bands  were  quantified 
and plotted. (B) Same as described in A for CD3-∆. (C) Radiolabeled   
CD3-∆ was immunoisolated after the indicated chase times from cells 
lacking HRD1 transfected with an empty plasmid (mock; lanes 1–3), a 
plasmid for expression of wild-type HRD1 (lanes 4–6), or a plasmid for 
expression of inactive HRD1 (HRD1*; lanes 7–9). Relevant bands were 
quantified and plotted. Molecular mass markers are shown on the left for 
all gels (given in kilodaltons).227 Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al.
in clearance of membrane-tethered and soluble BACE476 from 
the ER. Down-regulation of HRD1 obtained by specific RNAi 
(Fig. 4 A) slightly delayed disposal of BACE476 (Fig. 4 B, lanes 
4–6 and quantification of siHRD1). Down-regulation of GP78 
(Fig. 4 A) had no effect (Fig. 4 B, lanes 7–9 and quantification 
of siGP78). However, the combined inactivation of both HRD1 
and GP78 (Fig. 4 A) substantially delayed BACE476 disposal 
(Fig. 4 B, lanes 10–12 and quantifications siHRD1 + siGP78). 
The delay of BACE476 disposal obtained upon combined in-
activation of the HRD1 and of the GP78 pathways was com-
parable with the delay obtained upon cell exposure to classical 
ERAD inhibitors such as kifunensine or PS341 (Fig. S1 A). 
Collectively, these data show that GP78 can replace the inactive 
HRD1 and GP78 requirements for  
disposal of membrane-tethered and  
soluble BACE476
So far, we showed that deletion of HRD1 significantly interferes 
with disposal of the anchorless variants of BACE476 and CD3- 
(ERAD-LS substrates), leaving unaffected disposal of polypeptides 
with the same luminal domain, but tethered at the ER membrane 
(ERAD-LM substrates). This may indicate that HRD1 is not in-
volved in disposal of membrane-anchored ERAD-L substrates or 
that upon HRD1 deletion, surrogate pathways regulated by other 
membrane-embedded E3 ligases are engaged to ensure disposal.
To verify this, we next assessed the consequences of the 
individual and combined down-regulation of HRD1 and GP78 
Figure 4.  Consequences of HRD1 and GP78 
down-regulation on degradation of membrane-
tethered and soluble variants of BACE476 and 
CD3-. (A) The efficiency of siRNA-based HRD1 
and GP78 down-regulations were checked by 
immunoblotting.  Tubulin  is  a  loading  control. 
(B)  Radiolabeled  BACE476  was  immunoiso-
lated after the indicated chase times from cells 
expressing  a  scrambled  siRNA  (siSCR;  lanes 
1–3), an siRNA targeting HRD1 (siHRD1; lanes 
4–6), GP78 (siGP78; lanes 7–9), or both HRD1   
and GP78 (siHRD1/siGP78; lanes 10–12).   
Relevant  bands  were  quantified  and  plotted. 
(C–E) Same as described in B for BACE476∆, 
CD3-,  and  CD3-∆,  respectively.  Molecular 
mass markers are shown on the left for all gels 
(given in kilodaltons).JCB • VOLUME 188 • NUMBER 2 • 2010   228
association with the ERAD lectins OS-9 and XTP3-B (Mueller   
et al., 2006, 2008; Christianson et al., 2008; Hosokawa et al., 
2008) through association with the member of the glycosyl 
hydrolase 47 family EDEM1 (Cormier et al., 2009) or through 
association with luminal chaperones such as BiP or GRP94.
Our finding that only ERAD-LS substrates were strictly de-
pendent on active HRD1 prompted us to verify the involvement 
of SEL1L in clearance of ERAD-LS versus ERAD-LM substrates. 
To this end, kinetics of protein disposal was compared in mock-
treated cells (Fig. 5, siSCR) and in cells with reduced expres-
sion of SEL1L (Fig. 5, siSEL1L). Down-regulation of SEL1L 
(Fig. 5 A) only marginally slowed disposal of the ERAD-LM  
substrate BACE476 (Fig. 5 B, lanes 4–6 and quantifications) 
but substantially delayed degradation of the ERAD-LS substrate 
BACE476 (Fig. 5 C, lanes 4–6 and quantifications). Similarly, 
down-regulation  of  SEL1L  had  no  effect  on  degradation  of   
the ERAD-LM substrate CD3- (Fig. 5 D, lanes 4–6 and quan-
tifications)  but  fully  protected  the  anchorless  variant  of  the   
same folding-defective polypeptide from degradation (Fig. 5 E,   
lanes 4–6 and quantifications). Collectively, these findings 
showed  that  down-regulation  of  SEL1L  recapitulates  the   
phenotype obtained upon deletion (Figs. 2 and 3) or down-
regulation of HRD1 (Fig. 4). Inactivation of HRD1 or SEL1L 
had little or no effect on disposal of ERAD-LM substrates but 
dramatically interfered with clearance from the ER lumen of 
the same polypeptides when detached from the ER membrane 
(ERAD-LS substrates).
OS-9 and XTP3-B are interchangeable 
ERAD shuttles required for efficient 
disposal of ERAD-LS but not  
ERAD-LM substrates
The mammalian splice variants of OS-9 and XTP3-B constitute   
a group of proteins that have lectin-like domains with homol-
ogy  to  the  mannose-6-phosphate  receptor  family  (Munro, 
2001). So far, OS-9 or XTP3-B intervention in ERAD has 
only been shown for the model ERAD substrates NHK or Ri332 
(Bernasconi et al., 2008; Christianson et al., 2008; Hosokawa 
et al., 2008; Mueller et al., 2008; Alcock and Swanton, 2009; 
Hosokawa et al., 2009). The individual down-regulation of 
these ERAD lectins has generally no or mild phenotypes, and 
attempts to establish the involvement of OS-9 or XTP3-B 
variants in disposal of other glycosylated folding-defective 
polypeptides have been unsuccessful, thus questioning their 
relevance  as  general  regulators  of  protein  disposal  from   
the mammalian ER. Our data confirm that individual down-
  regulation of OS-9 (Fig. 5, A, B, and E, lanes 7–9 and quanti-
fications) or XTP3-B (Fig. 5, A, B, and E, lanes 10–12 and   
quantifications)  did  not  significantly  delay  disposal  of 
BACE476, BACE476, CD3-, and CD3-. However, com-
bined down-regulation of OS-9 and XTP3-B specifically re-
tarded disposal of the HRD1 client BACE476 (Fig. 5 C, lanes 
13–15 and quantifications) to a similar extent as down-regulation 
of SEL1L (lanes 4–6) and HRD1 (Fig. 4 C, lanes 4–6). Com-
bined down-regulation of OS-9 and XTP3-B also partially   
protected CD3- from disposal (Fig. 5 E, lanes 13–15). Thus, 
OS-9 and XTP3-B have redundant activities in the ER lumen 
HRD1 and that, vice versa, HRD1 can replace inactive GP78 to 
ensure efficient disposal of BACE476.
On the contrary, HRD1 down-regulation was sufficient to 
delay BACE476 disposal to a similar extent as 1,2-mannosidases 
or proteasome inactivation (Fig. 4 C, lanes 4–6 and quantifica-
tions; and Fig. S1 B). Down-regulation of GP78 had no effect 
on BACE476 degradation (Fig. 4 C, lanes 7–9), and combined 
inactivation of the two E3 ubiquitin ligases (Fig. 4 C, lanes 10–12) 
had the same inhibitory effect as the individual down-regulation 
of HRD1 (Fig. 4 C, quantification). This is in agreement with a 
model claiming that the presence or absence of a membrane anchor 
determines requirements for disposal of ERAD-L substrates. 
More  precisely,  deletion  of  the  membrane  anchor  converted 
BACE476 from an HRD1/GP78 client into an obligate client of 
the HRD1 pathway.
HRD1 and GP78 requirements for  
efficient disposal of membrane-tethered  
and soluble CD3-
Next, we assessed the contribution of HRD1 and GP78 in clear-
ance from the ER of CD3- and CD3-. Down-regulation of 
HRD1 did not affect degradation of CD3- (Fig. 4 D, lanes 4–6 
and quantifications). Down-regulation of GP78 did delay CD3-   
disposal (Fig. 4 D, lanes 7–9), and the additional inactivation of 
HRD1 did not further protect this folding-defective polypeptide 
from ERAD (Fig. 4 D, lanes 10–12 and quantifications). These 
data  are  consistent  with  findings  reporting  that  CD3-  is  a   
client of the GP78 machinery (Fang et al., 2001; Zhong et al., 
2004; Ballar et al., 2006; Chen et al., 2006; Tsai et al., 2007) 
and with data showing that CD3- disposal remains unaffected 
upon inactivation of the HRD1 pathway (Fig. 3 A; Yang et al., 
2007). The incomplete inhibition of CD3- disposal upon in-
activation of GP78 (Fig. 4 D) is consistent with data showing 
that at least another E3 ligase, RFP2 (Lerner et al., 2007), con-
tributes to CD3- clearance from the ER lumen.
In agreement with our model predicting that changes in 
substrate tethering to the membrane determine selection of the 
ERAD  pathway  regulating  clearance  of  ERAD-L  substrates 
from the ER, HRD1 down-regulation was sufficient to substan-
tially delay CD3- disposal (Fig. 4 E, lanes 4–6 and quantifica-
tions), whereas down-regulation of GP78 had no effect (Fig. 4 E, 
lanes 7–9). Combined inactivation of the two ligases (Fig. 4 E, 
lanes 10–12) had the same inhibitory effect on CD3- disposal 
as the individual down-regulation of HRD1. Thus, deletion of 
the membrane anchor converted CD3- from a GP78/RFP2 
client into an obligate client of the HRD1 pathway.
SEL1L is required for efficient disposal of 
ERAD-LS substrates
Our data show a stringent requirement of HRD1 for degrada-
tion of the ERAD-LS substrates BACE476 and CD3-. The 
same polypeptides might exploit the HRD1 and/or the GP78 
and/or other E3 ligases for efficient disposal when anchored at 
the ER membrane. The complex built around HRD1 contains 
several  proteins  that  are  excluded  from  the  GP78  complex. 
Among them, SEL1L plays a crucial role in protein disposal by 
recruiting ERAD substrates either directly or indirectly through 229 Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al.
Down-regulation of SEL1L and HRD1 
allows identification of OS-9.1 as delivery 
factor for BACE476
In an attempt to identify ERAD factors interacting with ERAD-LS 
versus ERAD-LM substrates, BACE476 was tagged with an 
EFRH tetrapeptide (which is recognized by 1, a monoclonal 
antibody described in Paganetti et al., 2005), whereas BACE476 
was HA tagged. The two proteins were ectopically coexpressed 
in mock-treated cells (siSCR; Fig. 6, A and B, lane 1; Fig. S4) 
or in cells with reduced levels of HRD1 (Fig. 6, A and B, lane 2), 
GP78 (Fig. 6, A and B, lane 3), HRD1 and GP78 (Fig. 6, A and B, 
lane 4), SEL1L (Fig. 6, A and B, lane 6), OS-9 (Fig. 6, A and B, 
lane 7), XTP3-B (Fig. 6, A and B, lane 8), and OS-9 and XTP3-B   
(Fig. 6, A and B, lane 9). Cells were lyzed under conditions that   
preserve many substrate–chaperone interactions (Molinari et al.,   
2002). BACE476-1 (Fig. 6 A) and BACE476-HA (Fig. 6 B) 
were individually immunoisolated with the appropriate anti-tag 
so  that  their  combined  inactivation  might  be  required  to   
substantially delay disposal. NHK is an exception to this rule 
because individual down-regulation of OS-9 is sufficient to 
significantly delay ERAD (Bernasconi et al., 2008; Christian-
son  et  al.,  2008).  Moreover,  our  data  show  that  OS-9  and 
XTP3-B intervention is only required for disposal of ERAD-LS 
substrates that must be shuttled from the ER lumen to the ER 
membrane-embedded HRD1 complex for efficient clearance 
from the ER. For this reason, we define OS-9 and XTP3-B   
as  ERAD  shuttles.  Disposal  of  the  same  glycopolypeptides 
tethered  to  the  ER  membrane  (ERAD-LM  substrates)  pro-
gressed  unperturbed  even  upon  substantial  reduction  of  the 
cellular content of OS-9 and XTP3-B. This shows that the two 
ERAD shuttles do not intervene in disposal of membrane-teth-
ered N-glycosylated polypeptides with luminal defects or that 
they can efficiently be replaced by a surrogate factor upon their 
combined inactivation (see Discussion).
Figure 5.  Disposal of soluble misfolded poly-
peptides relies on SEL1L and both OS-9 + 
XTP3-B.  (A)  The  efficiency  of  siRNA-based 
SEL1L,  OS-9,  and  XTP3-B  down-regulations 
were checked by immunoblotting. Tubulin is 
a loading control. (B) Radiolabeled BACE476 
was immunoisolated after the indicated chase 
times from cells expressing a scrambled siRNA 
(siSCR; lanes 1–3), an siRNA targeting SEL1L 
(siSEL1L; lanes 4–6), OS-9 (siOS-9; lanes 7–9),   
XTP3-B (siXTP3-B; lanes 10–12), or both XTP3-B 
and  OS-9  (siXTP3-B/siOS-9;  lanes  13–15). 
Relevant bands were quantified and plotted. 
(C–E) Same as described in B for BACE476∆, 
CD3-, and CD3-∆, respectively. Molecular 
mass markers are shown on the left for all gels 
(given in kilodaltons).JCB • VOLUME 188 • NUMBER 2 • 2010   230
machinery independent of the mechanisms regulating disposal 
of the membrane-tethered version of the proteins under investi-
gation. To challenge our model, we decided to determine re-
quirements for disposal of a soluble ERAD substrate and to 
verify how requirements would change upon addition of a trans-
membrane anchor. To this end, we selected a classical ERAD-L 
substrate, the NHK variant of the secretory protein 1-antitrypsin 
(Liu et al., 1997). As previously shown in other cell lines   
(Bernasconi et al., 2008), we confirm that a fraction of NHK es-
capes ER retention and is secreted extracellularly (15% of the 
labeled protein in HeLa cells; Fig. S2 F). The expectations were 
that disposal of this ERAD-LS protein should substantially be 
delayed  upon  inactivation  of  the  E3  ligase  HRD1  and  that   
the strict dependency on HRD1 should be relieved when the 
folding-defective  polypeptide  is  converted  in  a  membrane-
  tethered ERAD-LM protein. Reduction of the intralumenal level 
of HRD1 (Fig. 7 A, lanes 4–6) substantially inhibited NHK deg-
radation without affecting secretion of the protein (Fig. S2 F). 
The combined inactivation of the GP78 pathway did not further 
protect the protein from disposal (Fig. 7 A, lanes 10–12). The 
intervention of HRD1 was not surprising because both SEL1L 
(Christianson et al., 2008; unpublished data) and OS-9 (Bernasconi 
et al., 2008; Christianson et al., 2008) have been shown to par-
ticipate in NHK disposal. Thus, NHK behaves as a bonafide 
ERAD-LS protein as defined above, which shows strict depen-
dency on the HRD1 pathway for disposal.
Tethering of NHK at the ER membrane was obtained 
by appending the membrane anchor of BACE501 (NHKBACE;   
Fig. 1) or the membrane anchor of CD3- (NHKCD3; Fig. 1) 
at the C terminus of NHK (see Materials and methods). The 
membrane anchor of BACE501 does not contain misfolded or 
retention signals. Consistently, BACE501 is efficiently trans-
ported at the cell surface when the protein is ectopically ex-
pressed in cultured cells (Vanoni et al., 2008). However, it 
is not entirely clear whether the transmembrane domain of 
CD3- is free of misfolding signal. Anchoring of NHKBACE  
and  of  NHKCD3  at  the  ER  membrane  was  confirmed  by   
subcellular fractionation as described previously (Fig. S5,   
A and B, respectively; Olivari et al., 2005). Both proteins were 
degraded from cells with slightly faster kinetics compared with   
their soluble counterpart (Fig. 7, A [NHK], B [NHKBACE], and 
C [NHKCD3]; compare lanes 1–3). Degradation was efficiently 
antibody together with their interacting partners. The amount 
of proteins separated in SDS-PAGE and blotted on a PVDF 
membrane was normalized to ensure equal loading of BACE in 
each lane (Fig. 6, A and B, bottom). The PVDF membrane was 
probed with antibodies to GRP94, BiP, and OS-9 to determine 
whether these ER chaperones, claimed to be involved in ERAD, 
were found in complexes sufficiently stable to survive the cell 
lysis and immunoprecipitation protocols. The case for GRP94   
is unclear, as variations in the amount of this chaperone co-
precipitated with BACE476-1 (Fig. 6 A) or BACE476-HA 
(Fig. 6 B) were too small to be considered significant. Variations   
were also small for BiP. However, a stabilization of BACE476– 
BiP  complexes  was  observed  upon  inactivation  of  HRD1 
(Fig. 6 A, lane 2), HRD1 + GP78 (Fig. 6 A, lane 4), SEL1L 
(Fig. 6 A, lane 6), and upon combined inactivation of OS-9 + 
XTP3-B (Fig. 6 A, lane 9). These variations were reproducible 
even when BACE476-1 was individually expressed in cells 
subjected to transient interferences (unpublished data). Stabili-
zation of BACE476–BiP complexes upon disassembly of the 
HRD1 dislocon shows that BiP contributes to delivery of termi-
nally misfolded polypeptides to this machinery.
Our analysis also revealed a significant stabilization of 
BACE476–OS-9.1  complexes  in  cells  subjected  to  HRD1 
(Fig.  6 A,  lane  2),  HRD1  +  GP78  (less  evident;  Fig.  6 A, 
lane 4), or SEL1L down-regulations (Fig. 6 A, lane 6). Under 
the same conditions, and actually in the same cells because 
BACE476-1 and BACE476-HA were coexpressed, we were 
unable to detect stabilization of complexes between BACE476 
and the ER chaperones tested (Fig. 6 B).
The  stabilization  of  BACE476–OS-9.1  complexes 
(and possibly of BACE476–XTP3-B complexes [an anti-
body to detect endogenous XTP3-B is unfortunately not avail-
able]) when SEL1L or HRD1 is not available for substrate 
delivery is consistent with a sequential involvement of these 
components during channeling of BACE476 into the cytosol 
for disposal.
Disposal of the classical ERAD-LS 
substrate NHK and of its two ERAD-LM 
variants, NHKBACE and NHKCD3
So far, we showed that deletion of the membrane anchor of 
ERAD-L substrates confers a strong dependency on the HRD1 
Figure 6.  Trapping of BACE476∆ by OS-9.1   
upon  inactivation  of  the  HRD1  pathway.  
(A) BACE476∆ was immunoisolated from deter-
gent extracts of cells incubated with a scrambled   
siRNA,  and  siRNA  targeting  HRD1,  GP78, 
GP78,  and  HRD1  (lanes  1–4)  and  SEL1L,   
OS-9, XTP3-B, and XTP3-B + OS-9 (lanes 6–9, 
respectively). Proteins were separated in SDS 
polyacrylamide gels and transferred on PVDF.   
The membranes were blotted with antibodies rec-
ognizing endogenous GRP94, BiP, OS-9.1, and 
OS-9.2 and BACE476∆ as a loading control.   
(B) Same as described in A for BACE476. Arrow-
heads indicate the coprecipitated OS-9.1. TCE, 
total cell extract; IP, immunoprecipitation.231 Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al.
saccharides displayed on terminally misfolded polypeptides. 
Demannosylated oligosaccharides recruit ERAD lectins such 
as Yos9p in S. cerevisiae and OS-9 and XTP3-B splice variants 
in mammals (Bernasconi et al., 2008; Christianson et al., 2008; 
Hosokawa et al., 2008, 2009; Mueller et al., 2008; Quan et al., 
2008; Tamura et al., 2008; Wang and Ng, 2008; Alcock and 
Swanton, 2009; Clerc et al., 2009). ERAD lectins and luminal 
chaperones such as BiP, GRP94, and protein disulfide isomer-
ase deliver terminally misfolded polypeptides to dislocons at 
the ER membrane. Dislocons contain a membrane-embedded E3 
ubiquitin ligase and several adaptor molecules with substrate-
recognition/modifying  domains  facing  the  luminal  and/or   
cytosolic side of the ER membrane. Altogether, these multi-
meric  protein  complexes  regulate  the  export  of  terminally 
misfolded  polypeptides  across  the  ER  membrane  and  their 
polyubiquitylation  that  facilitates  proteasomal  intervention 
(Kostova et al., 2007; Nakatsukasa and Brodsky, 2008; Ravid 
and Hochstrasser, 2008; Hirsch et al., 2009).
In S. cerevisiae, the primary role of demannosylation of 
folding-defective  polypeptides  is  the  exposure  of  the  1,6-
bonded mannose residue j (Fig. 8 A) that recruits the ERAD 
lectin Yos9p (Quan et al., 2008; Clerc et al., 2009). Our data 
show that in mammalian cells, even though demannosylation is 
required for disposal of N-glycosylated ERAD-LS (for soluble; 
detached from the ER membrane) and ERAD-LM (for mem-
brane tethered) substrates, OS-9 and XTP3-B are only required 
for disposal of ERAD-LS substrates. We have defined OS-9 and 
XTP3-B as ERAD shuttles because they associate with soluble, 
misfolded polypeptides in the ER lumen and deliver them at 
dislocons embedded in the ER membrane. Our data show that 
OS-9 and XTP3-B are interchangeable in this function, thus 
inhibited  upon  inactivation  of  ER  mannosidases  and  cyto-
solic proteasomes (unpublished data). In agreement with our 
model, conversion of NHK in an ERAD-LM substrate sub-
stantially relieved HRD1 dependency. In fact, disposal of both 
NHKBACE (Fig. 7 B) and NHKCD3 (Fig. 7 C) was unaffected 
upon reduction of the intraluminal level of HRD1. Disposal 
of the membrane-tethered versions of NHK was only par-
tially delayed upon inactivation of both the HRD1 and GP78 
pathways (Fig. 7, B and C, lanes 10–12), hinting at the pos-
sible intervention of alternative ERAD pathways in disposal 
of NHK when anchored at the ER membrane.
Discussion
The protein folding, quality control, and disposal machiner-
ies operating in the mammalian ER lumen determine the fate 
of thousands of gene products, each one characterized by 
unique structural, biophysical, and biochemical properties. 
The covalent addition of preassembled glucose3-mannose9-N-
acetylglucosamine2-oligosaccharides  on  nascent  polypeptide 
chains (Fig. 8 A) and their processing generate unique signals 
decoded by ER-resident lectins, glucosyl transferases, and gly-
cosyl hydrolases that determine prolongation or interruption of 
folding and onset of disposal (Aebi et al., 2009; for review see   
Molinari, 2007). Current models claim that a series of 1,2-
mannosidases (MnsIp and HtmIp in S. cerevisiae; Quan et al.,   
2008; Clerc et al., 2009), ERManI, EDEM proteins, and/or 
Golgi  mannosidases  in  mammalian  cells  (Liu  et  al.,  1997; 
Hirao et al., 2006; Olivari et al., 2006; Hosokawa et al., 2007; 
for review see Aebi et al., 2009) slowly remove terminal 1,2-
bonded mannose residues (Fig. 8 A, dark green) from oligo-
Figure 7.  Involvement of HRD1 and GP78 in 
disposal of soluble and membrane-tethered 
NHK  variants.  (A)  Radiolabeled  NHK  was   
immunoisolated  after  the  indicated  chase 
times from cells expressing a scrambled siRNA 
(siSCR; lanes 1–3), an siRNA targeting HRD1 
(siHRD1;  lanes  4–6),  GP78  (siGP78;  lanes   
7–9), or both HRD1 and GP78 (siHRD1/siGP78; 
lanes 10–12). Relevant bands were quantified 
and plotted. (B and C) Same as described 
in A for NHKBACE and NHKCD3, respectively.   
Molecular mass markers are shown on the left 
for all gels (given in kilodaltons).JCB • VOLUME 188 • NUMBER 2 • 2010   232
and the possibility for nonnative polypeptides to be retained in 
the calnexin cycle are missing. Removal of mannose g as a sig-
nal required for polypeptide disposal would therefore make lit-
tle sense, whereas removal of mannose residues i and k is crucial 
because it allows an active segregation of misfolded polypep-
tides upon Yos9p association (Aebi et al., 2009).
The mammalian ER membrane hosts several E3 ubiquitin 
ligases that might potentially contribute to dislocation/disposal 
of misfolded proteins from the ER (Kostova et al., 2007;   
Nakatsukasa and Brodsky, 2008; Ravid and Hochstrasser, 2008; 
Hirsch et al., 2009). Individual or combined inactivation of two 
of them, namely HRD1 and GP78, was sufficient to signifi-
cantly delay disposal of classical ERAD-L substrates such as 
BACE, CD3-, and NHK variants. For folding-defective poly-
peptides  detached  from  the  ER  membrane  (ERAD-LS  sub-
strates), efficient disposal required HRD1, SEL1L, and OS-9   
or XTP3-B. The stringent requirement for components of the 
HRD1 pathway was relieved when the very same luminal do-
mains were tethered to the ER membrane. Thus, ERAD-LM 
substrates do use, or can eventually engage, alternative ERAD 
pathways when the HRD1 pathway has been shut down. Such 
complexity is absent or has not been reported so far in the case 
of  S.  cerevisiae  in  which  soluble  and  membrane-tethered 
ERAD-L substrates are degraded by a unique pathway built 
around the E3 ubiquitin ligase Hrd1p (Taxis et al., 2003; Vashist 
and Ng, 2004; Carvalho et al., 2006; Willer et al., 2008).
It can be envisioned that access to membrane-embedded 
dislocons might be facilitated by lateral diffusion in the lipid bi-
layer when folding-defective polypeptides are tethered to the 
ER membrane. However, misfolded proteins floating in the ER 
lumen might be more dependent on luminal ERAD shuttles   
(e.g., OS-9 and XTP3-B) that direct them from the ER lumen to 
dislocons embedded in the ER membrane. HRD1 accessory 
factors such as OS-9, XTP3-B, and their membrane receptor 
SEL1L are excluded from complexes containing GP78 or other 
E3 ubiquitin ligases (Hosokawa et al., 2008; Morito et al., 2008; 
Alcock and Swanton, 2009). Thus, the HRD1 complex seems 
better equipped to recruit soluble folding-defective polypep-
tides at the ER membrane.
explaining the mild, if any phenotype caused by their individual 
inactivation reported so far in the literature.
At least for ERAD-LM substrates, the primary role of de-
mannosylation might not be the recruitment of OS-9 and XTP3-B 
because the two ERAD shuttles are dispensable for disposal   
of N-glycosylated polypeptides tethered at the ER membrane. 
One could envision that another lectin decodes the ERAD sig-
nal generated upon demannosylation of ERAD-LM substrates 
when OS-9 and XTP3-B are not available. If this would hold 
true, this yet to be characterized factor cannot act as surrogate 
ERAD lectin for soluble, misfolded glycopolypeptides.
Alternatively,  the  primary  role  of  demannosylation  of 
ERAD-LM substrates could be to elicit extraction of folding- 
defective  polypeptides  from  the  calnexin  chaperone  system, 
which is a rate-limiting step in disposal of N-glycosylated pro-
teins (for review see Molinari, 2007). The mammalian ER con-
tains  the  quality  control  enzyme  UDP-glucose–glycoprotein 
glucosyl  transferase  (UGT1;  Parodi,  2000).  The  activity  of 
UGT1 preserves the glucose residue l (Fig. 8 A), which is re-
quired for the association of nonnative polypeptides with the 
lectin chaperones calnexin and calreticulin (Hammond et al., 
1994).  Retention  of  nonnative  polypeptides  in  the  calnexin 
chaperone system protects them from degradation (Caramelo 
and Parodi, 2008; Aebi et al., 2009). Therefore, removal of 
mannose g, which is the only hexose that can be reglucosylated 
by the UGT1, causes the irreversible extraction of terminally 
misfolded polypeptides from the folding machinery and is cru-
cial to initiate a series of events eventually leading to polypep-
tide  disposal.  Consistently,  pharmacologic  inactivation  of 
1,2-mannosidases (Molinari et al., 2002) or reduction of their 
intraluminal level (Molinari et al., 2003) substantially delays 
release of terminally misfolded polypeptides from calnexin. As 
a further indication that removal of mannose g is relevant for 
mammalian ERAD, recent data have shown that substrate de-
mannosylation is required in mutant cell lines characterized by 
addition on nascent chains of aberrant oligosaccharides in which 
mannose g is the only removable 1,2-bonded mannose (Fig. 8 B; 
Ermonval et al., 2001; Moremen and Molinari, 2006; Olivari 
et al., 2006). In S. cerevisiae, a functional orthologue for UGT1 
Figure  8.  Structure  and  composition  of 
N-linked  glycans.  (A)  The  Asn-linked  core 
oligosaccharide is composed of two N-acetyl-
glucosamines (squares), nine mannoses (circles;   
the cleavable 1,2-bonded mannoses are shown   
in dark green), and three glucoses (triangles). 
The linkages are indicated, and letters a–n are 
assigned. a–c define the three oligosaccharide 
branches. (B) Aberrant oligosaccharide trans-
ferred to nascent polypeptide chains in B3F7 
cells (Moremen and Molinari, 2006).233 Disposal of ERAD-LS versus ERAD-LM substrates • Bernasconi et al.
Cell Lines, transient transfections, RNAis, metabolic labeling, 
immunoprecipitations, immunoblots, and analysis of data
Hrd1
/ and wild-type MEF cells were grown in DME supplemented with 
10% FBS. Cells at 80–90% confluence in a 6-cm tissue culture plate were 
transfected with the expression plasmid of interest (4 µg for single trans-
fections and 6 µg total DNA for double transfections) using Lipofectamine 
2000 (Invitrogen) according to the manufacturer’s instructions. Experiments 
were normally performed 17 h after transfection. Expression of all proteins 
has been confirmed by immunoprecipitation (Fig. S2). For siRNA-based 
interference, HeLa cells were grown in MEM Alpha supplemented with 
10% FBS. Cells at 50% confluence in a 3.5-cm tissue culture plate were 
transfected with 50 pmol/dish siRNA duplex (Applied Biosystems) using 
Lipofectamine 2000 according to the manufacturer’s instructions. 4 h after 
transfection,  the  medium  was  replaced  with  MEM  Alpha  supplemented   
with 1% nonessential amino acids (Invitrogen). 30 h after siRNA trans-
fection, cells were transfected with the expression plasmids of interest.   
Experiments were performed 48 h after RNAi transfection. siRNA targeting   
sequences  used  are  as  follows:  HRD1,  5-GGUGAUGGGCAAGGUGUUC-3;   
GP78, 5-GACGGAUUCAAGUACCUUU-3; SEL1L, 5-GGCUAUACU-
GUGGCUAGAA-3;  OS-9.1  and  OS-9.2,  5-CAUCAUCCAGGAGA-
CAGAG-3; XTP3-B1 and XTP3-B2, 5-AGCAGUUGUUCCUACAGAA-3. 
When  detection  of  endogenous  target  proteins  was  impossible,  the   
efficiency of siRNA was confirmed by the significant reduction in expression 
of ectopically expressed targets (i.e., HRD1, GP78, and XTP3-B).
18  h  after  transfection,  cells  were  starved  for  20  min  in  Met/ 
Cys-free medium, pulsed for 10 min with 50 µCi [S
35]Met/Cys, and chased 
for the indicated times with MEM Alpha supplemented with 5 mM cold 
Met/Cys. PNS was prepared by solubilization of cells in 400 µl/3.5-cm 
dish (or 800 µl/6-cm dish) ice-cold 2% CHAPS (Anatrace) in Hepes-buffered 
saline (HBS), pH 6.8, containing 20 mM N-ethylmaleimide and protease 
inhibitors. CHAPS-insoluble material was separated by centrifugation at 
10,000 g for 10 min. Immunoprecipitations were performed by adding 
protein A beads (1:10 wt/vol swollen in HBS; Sigma-Aldrich) with the   
selected antibody and incubated for 2 h at 4°C.
Immunoprecipitates  were  extensively  washed  (three  times  for   
10 min) with 0.5% CHAPS in HBS, resuspended in sample buffer, boiled 
for 5 min, and finally separated in SDS-PAGE. Gels were exposed to films 
(BioMax; Kodak) and scanned with a scanner (Agfa). Relevant bands were 
quantified by ImageQuant software (Molecular Dynamics). Because of the 
number of Petri dishes that can be handled in parallel, to analyze all condi-
tions in a single transfection round, we had to perform three-point kinetics. 
Protein half-lives were confirmed by separate, independent experiments   
using additional chase times. Immunoblots were performed using the SNAP 
i.d. protein detection system (Millipore). All primary antibodies were used 
at 1:200–1:333 dilutions. Secondary antibodies were HRP conjugated 
and used at 1:10,000 dilutions. The ECL Plus detection system was   
obtained from GE Healthcare.
Subcellular fractionation and separation of membrane versus  
luminal content
Metabolically labeled cells expressing NHKBACE and NHKCD3 were exten-
sively washed with isotonic buffer and resuspended in 800 µl of homog-
enization buffer (10 mM triethanolamine, 10 mM acetic acid, 250 mM 
sucrose, 20 mM NEM, 1 mM EDTA, and a cocktail of protease inhibi-
tors, pH 7.4; Olivari et al., 2005). Cells were broken with 10 passages 
through a 25G1 needle. After nuclear supernatants were subjected to ultra-
centrifugation (45 min at 200,000 g in TLA 120.2), the endomembrane- 
containing pellet was extensively washed, resuspended in 500 µl 100 mM 
Na2CO3, and incubated for 25 min on ice for carbonate extraction. After 
an additional ultracentrifugation step (45 min for 200,000 g), the super-
natant was harvested. The endomembrane fraction was washed once with 
100 mM Na2CO3 (35 min at 200,000 g) and resuspended in 800 µl of 
lysis buffer. Insoluble material was removed after 25 min on ice by 10 min 
centrifugation at 200,000 g. The ER luminal content and the endomem-
brane fraction were subjected to immunoprecipitation against calnexin, 
calreticulin, and NHKBACE or NHKCD3.
Semiquantitative RT-PCRs
MEF  cells  were  mock  treated  or  incubated  for  12  h  with  2.5  µg/ml   
tunicamycin. Cells were lyzed in TRIzol reagent (Invitrogen), and RNA was 
isolated according to the instructions of the manufacturer. 2 µg RNA was 
used for cDNA synthesis using reverse transcription (SuperScriptII; Invit-
rogen) and oligo(dT) (Invitrogen). RT-PCR was performed using TaqDNA 
polymerase (Invitrogen) with transcript-specific primers: unspliced + spliced 
Xbp1 (forward), 5-AAACAGAGTAGCAGCTCAGACTGC and (reverse) 
Notably,  misfolded  proteins  lacking  a  transmembrane   
anchor  might  fall  outside  the  ERAD-LS  group  and  show   
little or no dependency on conventional ERAD shuttles that 
would channel them to the HRD1 complex. For example, ATZ 
and serpins do not belong to the ERAD-LS group because   
they form polymeric deposits that cells remove from the ER by 
activating  multiple  proteasome-dependent  and  proteasome-
  independent disposal pathways (see Introduction; Perlmutter, 
2006; Shen et al., 2006; Granell and Baldini, 2008; Kroeger   
et al., 2009; Rutledge et al., 2009). Another example is ApoB, 
a protein that lacks a transmembrane anchor but is actually 
membrane  associated  in  the  lipid  ligand–deficient  state   
that triggers its disposal (Brodsky and Fisher, 2008), and as 
such,  may  engage  alternative,  ERAD  shuttle–independent   
disposal pathways.
It remains to be established what determines the ERAD 
pathway selection for ERAD-LM substrates. For example, why 
membrane-anchored canonical ERAD substrates such as CD3-  
(Figs. 3–5) require GP78 and/or RFP2 for efficient disposal 
(Fang et al., 2001; Zhong et al., 2004; Ballar et al., 2006; Chen 
et al., 2006; Lerner et al., 2007; Tsai et al., 2007), whereas others 
such as BACE476 (Figs. 2, 4, and 5), NHKBACE, and NHKCD3 
(Fig. 7) can use the HRD1, the GP78, and possibly other path-
ways. Certainly, our observations are consistent with the emerg-
ing picture that protein quality control in the mammalian ER 
conserves regulatory factors and basic mechanisms operating in 
the ER of the budding yeast but is characterized by additional 
levels of complexity. This is probably required to ensure effi-
ciency of protein biogenesis and maintenance of homeostasis in 
the context of multicellular systems.
Materials and methods
Expression plasmids, antibodies, and inhibitors
The pCIneo plasmids encoding for CD3- and XTP3-B were provided 
by  S.  Fang  (University  of  Maryland  Biotechnology  Institute,  Medical 
Biotechnology Center, Baltimore, MD) and C. Niehrs (German Cancer 
Research Center, Heidelberg, Germany), respectively. Plasmids for ex-
pression of BACE, NHK, and HRD1 variants were described previously 
(Molinari et al., 2003; Yagishita et al., 2005; Bernasconi et al., 2008).   
CD3-  was  prepared  by  inserting  a  stop  codon  (primer  sequence:   
5-GACTCGGGCACCATGGAGTTCCGACACTGAGCTGGTGTCAT-
CTTC-3) before the membrane anchor of CD3- using the site-directed 
mutagenesis  kit  (Agilent  Technologies).  The  membrane-tethered  vari-
ants of NHK (NHKBACE and NHKCD3) were generated by appending at   
the protein C terminus the amino acids PQTDESTLMTIAYVMAAICALFML-
PLCLMVCQWRCLRCLRQQHDDFADDISLLK (which correspond to residues 
448–501 of BACE501) or VELDSGTMA GVIFIDLIATLLLALGVYCFAGH-
ETGRPSGAAEVQALLKNEQLYQPLRDREDTQYSRLGGNWPRNKKS (which 
correspond to residues 96–173 of CD3-). Transmembrane segments 
are  italicized.  DNA  preparations  were  obtained  using  commercially 
available purification kits (Sigma-Aldrich). The nucleotide sequences of 
all plasmids were verified on both strands. Antibodies to BACE, NHK, 
and OS-9 were described previously (Bernasconi et al., 2008). Anti-
body to tubulin was obtained from ABM. Antibodies to GP78 and SEL1L 
were provided by Y. Ye (National Institute of Diabetes and Digestive   
and Kidney Diseases, National Institutes of Health, Bethesda, MD) and 
H.  Ploegh  (Whitehead  Institute  for  Biomedical  Research,  Cambridge, 
MA). Antibodies to BiP, EDEM1, and GRP94 were obtained from Santa 
Cruz Biotechnology, Inc., Sigma-Aldrich, and Thermo Fisher Scientific, 
respectively. The proteasome inhibitor PS341 was provided by Millen-
ium Pharmaceuticals, Inc. and was used at a concentration of 9 µM. 
Kifunensine was obtained from TRC, Inc. and was used at a concentra-
tion of 100 µM.JCB • VOLUME 188 • NUMBER 2 • 2010   234
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